Ki67 Labelling Index predicts clinical outcome and survival in oral squamous cell carcinoma

Authors

  • Amol Ramchandra Gadbail Indira Gandhi Government Medical College and Hospital, Department of Dentistry, Nagpur, Maharashtra
  • Sachin C Sarode Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Sant-Tukaram Nagar, Department of Oral Pathology and Microbiology, Pimpri
  • Minal S Chaudhary Datta Meghe Institute of Medical Sciences, Sharad Pawar Dental College & Hospital, Department of Oral Pathology and Microbiology, Sawangi (M), Wardha, Maharashtra
  • Shailesh M Gondivkar Government Dental College & Hospital, Department of Oral Medicine and Radiology, Nagpur, Maharashtra
  • Satyajit Ashok Tekade Modern Dental College & Research Centre, Department of Oral Pathology and Microbiology, Gandhi Nagar, Indore, Madhya Pradesh 453112
  • Monal Yuwanati People’s University, People’s College of Dental Science & Research Centre, Department of Oral Pathology and Microbiology, Bhopal, Madhya Pradesh
  • Shankargouda Patil Jazan University, College of Dentistry, Division of Oral Pathology, Department of Maxillofacial Surgery and Diagnostic Sciences, Jazan

DOI:

https://doi.org/10.1590/1678-7757-2020-0751

Keywords:

Oral Squamous Cell Carcinoma, Ki67 Labelling Index, Proliferation, Prognosis, Survival

Abstract

Objective: To investigate the Ki 67 expression and its correlation with clinicopathological features and 3 years as well as 5 years survival rate in oral squamous cell carcinoma (OSCC). Methodology: Total 217cases of OSCC primarily treated with surgery with or without radiation were included. All patients were followed up for 3 years and 150 were followed up of 5 years for disease free survival. The immunohistochemistry was carried out on neutral buffered formalin fixed paraffin embedded tissue to evaluate the expression of Ki67. Results: The Ki67 labeling index (LI) was significantly higher with respect to adverse clinicopathological parameters such as histopathological grading (p<0.001), clinical TNM staging (p<0.001) and nodal metastasis (p<0.001). The OSCC patients survived for less than 3 and 5 years were showed significantly higher Ki67 LI as compared to diseases free survived more than 3 and 5 years(p<0.001). The three years survival rate of OSCC patient significantly higher with low Ki67 LI (≤45) 96.2%, followed by moderate Ki67 LI (46 to 60) 60.7% and high Ki67 LI (≥61) 37.7% (p<0.001). The five years survival rate of OSCC patient statistically significantly higher with low Ki67 LI (≤45)93.3%, followed by moderate Ki67 LI (46 to 60) 46.8% and Ki67 LI (≥61) 23.3% (p<0.001). Conclusion: The measurement of cell proliferative activity by using Ki67 antigen expression in individual OSCC might provide unique, predictive information on clinical outcome, prognosis and deciding treatment modalities in OSCC.

Downloads

Download data is not yet available.

Downloads

Published

2021-06-14

Issue

Section

Original Articles